Search

Your search keyword '"Giovanna Rametta"' showing total 2 results
Start Over Author "Giovanna Rametta" Journal scientific reports
2 results on '"Giovanna Rametta"'

1. Blockage of interleukin-1β with canakinumab in patients with Covid-19

Author

Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, and Federico Cappuzzo

Subjects
Medicine, Science
Abstract

Abstract There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p

Published
2020
Full Text
View/download PDF

2. Blockage of interleukin-1β with canakinumab in patients with Covid-19

Author

Luigi Lazzari-Agli, Andrea Boschi, Claudia Ravaglia, Lucia Rossi, Ilaria Valentini, Luca Santini, Paolo Bassi, Ilaria Panzini, Emanuele Russo, Rossella Romagnoli, Lorenza Landi, Federica Baldazzi, Marina Assirelli, Francesca Facondini, Ivana Valenti, Giovanna Rametta, Pierluigi Cataleta, E. Marchionni, Federico Cappuzzo, Fabio Pieraccini, Diana Giannarelli, Maurizio Fusari, and Raffaella De Giovanni

Subjects
Male, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Science, Interleukin-1beta, COVID-19, Diseases, Medical research, Health care, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Article, Disease-Free Survival, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Medicine, Humans, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Survival rate, Aged, Multidisciplinary, business.industry, SARS-CoV-2, Middle Aged, medicine.disease, COVID-19 Drug Treatment, Clinical trial, Hospitalization, Oxygen, Survival Rate, Pneumonia, Canakinumab, Cohort, Female, business, medicine.drug
Abstract

There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO2/FiO2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab (p 9/L, respectively, p p

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results